Skip to main content
Premium Trial:

Request an Annual Quote

Personalis, Mount Sinai Services to Offer Tumor Genome Profiling Tech

NEW YORK (GenomeWeb) – Personalis announced today that it has signed a letter of intent to offer its next-generation tumor sequencing and interpretation technology in Canada through a collaboration with Toronto-based lab and research services firm Mount Sinai Services.

Under the terms of the deal, the two will create a framework to offer Personalis' Accuracy and Content Enhanced (ACE) technology for clinical diagnostic and research tumor molecular profile sequencing and analysis, as well as immuno-oncology sequencing clinical trials, to customers throughout Canada.

Personalis currently sells the ACE CancerPlus test for solid tumors, which provides a report on 181 clinically relevant genes to provide tumor genomic profile data that can help guide therapy and research. The company also offers ACE ImmunoID assays for the analysis of tumor mutation burden and neoantigen identification.

"Mount Sinai Services has been a leader in advancing personalized medicine in Canada and understands the complexities and value of comprehensive and accurate analysis and interpretation in cancer research and clinical care," Personalis CEO John West said in a statement.

Mount Sinai Services Managing Director Azar Azad added that his company's "expertise in providing customized laboratory services, combined with the capabilities of the Personalis ACE Platform, will contribute to advancing translational medicine by providing a comprehensive solution for pharma discovery and development of cancer therapies, and personalized clinical diagnostic cancer care."

Specific terms of the deal were not disclosed.